Diamed Obesity S.R.L.

Clinical research at Diamed Obesity S.R.L. in Galati focuses strongly on cardiovascular diseases, with studies centered on atherosclerotic cardiovascular disease, elevated lipoprotein(a), hypertension, and broader heart risk reduction. These trials are mainly designed to test new therapies that may lower major cardiovascular events and improve long-term protection for people at high risk.

• Reducing the risk of heart attack, stroke, and other major cardiovascular events
• Studying treatments for elevated lipoprotein(a) and atherosclerotic disease
• Evaluating therapies for people with cardiovascular disease and related risk factors

Several studies also look at chronic kidney disease and systemic inflammation, reflecting an integrated approach to heart and kidney health.

Another important area of research is digestive system diseases, especially non-alcoholic steatohepatitis and related liver fibrosis. The trials in this field aim to improve liver health, slow disease progression, and assess whether emerging treatments can reduce liver-related clinical events in people affected by metabolic liver disease.

• Testing new options for non-alcoholic steatohepatitis with fibrosis
• Assessing whether treatment can improve liver histology
• Exploring ways to lower the risk of liver-related complications

This work highlights the connection between liver disease, obesity, and broader metabolic health.

Research in nutritional and metabolic diseases is a major part of the trial portfolio, covering obesity, overweight, type 1 diabetes, type 2 diabetes, hypertriglyceridemia, and severe hypertriglyceridemia. These studies are designed to evaluate treatment effectiveness, improve blood sugar control, and address abnormal lipid levels that contribute to long-term health risks.

• Improving glycemic control in type 1 and type 2 diabetes
• Evaluating therapies for obesity and overweight
• Lowering triglycerides and managing severe lipid disorders

The site’s diabetes and cardiology focus supports research that connects metabolic disease management with prevention of cardiovascular complications.